Presentation of a Novel Model for Evaluation of Commercialization of Research and Development: Case Study of the Pharmaceutical Biotechnology Industry

AuthorHassan Emamien
AuthorReza Radfaren
Issued Date2017-07-31en
AbstractThe current situation in Iran suggests an appropriate basis for developing biotechnology industries, because the patents for the majority of hi-tech medicines registered in developed countries are ending. Biosimilar and technology-oriented companies which do not have patents will have the opportunity to enter the biosimilar market and move toward innovative initiatives. The present research proposed a model by which one can evaluate commercialization of achievements obtained from research with a focus on the pharmaceutical biotechnology industry. This is a descriptive-analytic study where mixed methodology is followed by a heuristic approach. The statistical population was pharmaceutical biotechnology experts at universities and research centers in Iran. Structural equations were employed in this research.en
DOIhttps://doi.org/10.22037/ijpr.2017.2068en
KeywordEvaluationen
KeywordCommercialization indicesen
KeywordResearch and development pharmaceutical biotechnologyen
PublisherBrieflandsen
TitlePresentation of a Novel Model for Evaluation of Commercialization of Research and Development: Case Study of the Pharmaceutical Biotechnology Industryen
TypeOriginal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijpr-16-1214.pdf
Size:
529.25 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF